7 / 19
Page 59
Notes:
conferenceseries
.com
Volume 6
Journal of Neurological Disorders
ISSN: 2329-6895
CNS 2018
November 12-13, 2018
November 12-13, 2018 | Edinburgh, Scotland
4
th
International Conference on
Central Nervous System Disorders & Therapeutics
A case report of idiopathic hypereosinophilic syndrome (HES) in a rheumatoid arthritis patient
El-Hadary H F
1
, Dadour NM
2
, Ahmed H
3
and
Moanes D
3
1
Kasr Al-Ainy, School of Medicine, Cairo University, Egypt
2
Egyptian fellowship, Cairo, Egypt
3
ElKatib Hospital, Cairo, Egypt
H
ypereosinophilic syndrome (HES) is a disorder which is characterized by the persistence of eosinophilia that is associated
with damage to multiple organs. Anderson is the first one who described peripheral eosinophilia with tissue damage in
1968. Chusid defined the three features required for diagnosis of hypereosinophilic syndrome in 1975.The features are sustained
absolute eosinophil count (AEC) greater than >1500/µl which persists for longer than 6 months, No identifiable etiology for
eosinophilia and Signs and symptoms of organ involvement. Secondary causes of eosinophilia became more identifiable in a
proportion of cases that would have been classified as idiopathic hyper eosinophilic syndrome in the past due to advances in
the diagnostic techniques.Secondary eosinophilia is a cytokine-derived (interleukin-5 [IL-5]) reactive phenomenon. Parasitic
diseases are the most common cause, whereas in developed countries world widely, but allergic diseases are the most common
cause in developed countries. There are other causes such as: Malignancies, Metastatic cancer, Tcell lymphoma, colon cancer,
pulmonary eosinophilia, Loffler syndrome, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis, Connective
tissue disorders – Scleroderma, polyarteritis nodosa, Skin diseases, Inflammatory bowel disease, Sarcoidosis and Addison
disease. Clonal eosinophilia is diagnosed by bone marrow histology, cytogenetics, and molecular genetics. Like Acute leukemia.
drhalaelhadary@yahoo.comJ Neurol Disord 2018, Volume 6
DOI: 10.4172/2329-6895-C9-050